Integrum AB

Quotes

“The surgery was done by the book by Mr Paul Culpan. We’re delighted to be collaborating with him, The London Clinic and London International Patient Services. It’s an exciting restart for the OPRA™ Implant System program in the U.K. and we hope that this surgery will pave the way for a deeper collaboration moving forward.

Professor Rickard Brånemark

...the treatment of thumb amputees using bone-anchored percutaneous prostheses with the osseointegration technique seems to be a safe, durable method with excellent short- and medium-long follow-up results.

JAAOS study

Osseointegration is a potentially game changing technology in amputee care, and Dr Brånemark is bringing the most advanced osseointegration technology to our group

Professor Hugh Herr, Head of the MIT Media Lab Biomechatronics Group

We are very happy to have Blake join us to strengthen our team and our presence in the hugely important North American market.

Rutger Barrdahl, CEO at Integrum

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Integrum AB granted PMA (premarket approval) by the FDA for the OPRA[™]Implant System

Sat, Dec 19, 2020 00:30 CET

Integrum is both extremely pleased, and proud, to announce the PMA approval issued by the Food and Drug Administration (FDA) in the US for the OPRA[TM] Implant System as a class III medical device. Integrum is both extremely pleased, and proud, to announce the PMA approval issued by the Food and Drug Administration (FDA) in the US for the OPRA[TM] Implant System as a class III medical device. In a release posted by FDA today, the agency stated: “Today’s approval of the OPRA Implant System expands options for prostheses for individuals who have had above-the-knee

There are no items matching the current filter

There are no more items matching the current filter

Share

Quotes

Integrum AB granted PMA (premarket approval) by the FDA for the OPRA[™]Implant System

Subscribe